ASCO 2025: Breakthrough Cancer Trials, Innovative Therapies, and China's Rising Role

Cutting-Edge Cancer Research Takes Center Stage at ASCO 2025

The 2025 annual meeting of the American Society of Clinical Oncology (ASCO), held from May 31 to June 3 at Chicago's McCormick Place Convention Center, promises to showcase groundbreaking developments across the oncology field. Experts anticipate that many of the studies presented could significantly influence clinical practice and drug development strategies worldwide.

Jason Mouabbi, assistant professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, emphasized the importance of several key breast cancer trials that could reshape treatment paradigms. Meanwhile, Lore Gruenbaum, chief scientific officer at The Leukemia & Lymphoma Society, highlighted the excitement surrounding minimal residual disease (MRD) testing in multiple myeloma, describing it as a potential game-changer that may accelerate clinical development and benefit drugmakers substantially.

Focus on Breast and Blood Cancers

Among the anticipated presentations, research on breast and blood cancers stands out. Notably, Takeda and Protagonist Therapeutics will present data on rusfertide, an investigational hepcidin mimetic for polycythemia vera—a rare but serious blood malignancy. "Rusfertide is a promising emerging treatment option," experts noted, highlighting its potential to benefit patients unresponsive to standard therapies. The Phase III VERIFY study, whose topline data were released in March, revealed that rusfertide achieved treatment responses in 77% of patients compared to 33% on placebo. It also met key secondary endpoints by reducing phlebotomies, improving hematocrit control, and enhancing patient-reported outcomes.

Gruenbaum commented that although she had not yet reviewed the ASCO abstract, "the data available so far indicate the potential for Rusfertide to significantly reduce the need for phlebotomies and improve hematocrit control in patients with polycythemia vera," adding that improvements in quality of life could be very meaningful. VERIFY has earned a plenary session slot at the conference.

In breast cancer, AstraZeneca's Phase III SERENA-6 trial is generating substantial pre-conference interest. Mouabbi described it as “one of the most anticipated studies at ASCO.” The trial combines AstraZeneca's oral selective estrogen receptor degrader (SERD) camizestrant with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer exhibiting emergent ESR1 mutations. February data demonstrated a significant progression-free survival benefit compared to aromatase inhibitors, marking a potential paradigm shift by showing efficacy without requiring radiographic progression. SERENA-6 will also be presented in a plenary session.

Additional notable breast cancer data will come from AstraZeneca's DESTINY-Breast09 trial, evaluating the antibody-drug conjugate (ADC) Enhertu—with or without Roche's Perjeta—as a first-line therapy for HER2-positive metastatic breast cancer. Early announcements in April indicated a significant progression-free survival improvement, providing a less chemotherapy-intensive option with robust efficacy.

Other breast cancer highlights include Merck and Gilead's ASCENT-04/KEYNOTE-D19 trial, combining the anti-TROP2 ADC Trodelvy with Keytruda, and Pfizer and Arvinas' VERITAC-2 trial testing the PROTAC degrader vepdegestrant, which yielded mixed results in March.

Emerging Modalities: Bispecific and Trispecific Antibodies

Experts are keenly observing advancements in novel treatment modalities such as bispecific and trispecific antibodies, which hold promise for addressing so-called "cold tumors"—tumors less responsive to immunotherapies. Scott Kopetz, professor of Gastrointestinal Medical Oncology at MD Anderson, described bispecific antibodies as potentially heralding “a new era in VEGF-targeted therapies.” These therapies not only inhibit angiogenesis but also enhance immune responses, potentially offering breakthroughs in advanced solid tumors like castration-resistant prostate and gallbladder cancers.

Lore Gruenbaum noted that bispecific and trispecific antibodies are similarly opening new avenues in blood cancer treatment. ASCO 2025 will feature initial clinical data on two trispecific antibodies: Johnson & Johnson's JNJ-5322 and Ichnos Glenmark Innovation's ISB-2001, both aimed at relapsed/refractory multiple myeloma. Bispecific therapies for blood cancers are increasing in number and advancing toward regulatory approval, with developers also moving these agents into earlier treatment lines.

David Piwnica-Worms, chair of Cancer Systems Imaging at MD Anderson, highlighted exciting trends in radiopharmaceuticals focusing on early biomarker identification and novel isotopes. “The field is rapidly expanding with new isotopes and molecular targets,” he remarked, underscoring the innovation momentum in radiopharma.

China's Growing Influence in Oncology Innovation

China's rising prominence in oncology research was underscored by Truist Securities analysts, who noted that nearly one-third of ASCO presentations involve assets originating from Chinese companies. This reflects China's intensified research and development efforts and expanding global biotech innovation footprint.

Christiana Bardon, co-managing partner at biotech investment firm MPM BioImpact, observed that Chinese firms have evolved from producing "fast-follower drugs" to leading innovation with disruptive, first-in-class medicines. She highlighted Summit Therapeutics and its Chinese partner Akeso's PD-1/VEGF bispecific antibody ivonescimab, which could challenge Keytruda's dominant market position. Bardon also noted that major pharmaceutical companies, including BioNTech, Merck, and Pfizer, are acquiring additional PD(L)1 x VEGF candidates from China.

Paul Moore, chief scientific officer at Zymeworks, agreed that China's ascent fosters a more competitive oncology landscape, driving U.S. companies toward greater innovation and efficiency. Moore stressed the importance of intentional pipeline development, differentiation, and thoughtful trial design centered on disease biology and unique company expertise. He concluded that “real progress will come from therapies…that offer something new and impactful for patients,” with global competition fostering a “steel-sharpens-steel” effect in biopharma innovation.

Highlights

• ASCO 2025 showcases transformative cancer research, emphasizing breast, blood, melanoma, gastric, prostate, and lung cancers.
• Takeda and Protagonist's rusfertide shows promise in polycythemia vera, achieving a 77% treatment response in Phase III VERIFY trial.
• AstraZeneca's SERENA-6 trial indicates a potential paradigm shift in treating HR-positive, HER2-negative breast cancer with emergent ESR1 mutations.
• Bispecific and trispecific antibodies emerge as promising modalities for “cold tumors” and blood cancers, with novel agents entering clinical stages.
• Radiopharmaceutical innovation advances through new isotopes and early biomarker detection techniques.
• Chinese biotech firms significantly influence ASCO, driving global innovation and prompting competitive responses from major pharma players.
• Experts stress the need for pipeline differentiation, biologically informed trial design, and delivering truly novel therapies to improve patient outcomes.

Reference

https://www.biospace.com/drug-development/practice-changing-data-innovative-modalities-and-china-in-focus-at-asco25